Furthermore, SGLT2 inhibition decreased renal ACE expression and activity as well as the AT1R mRNA expression in the PCOS model, highlighting the important role of the intrarenal ACE in regulating BP in the PCOS model and as a new mechanism of the beneficial effect of the SGLT2 inhibitors. Here, ACE is linked to polycystic ovary syndrome.